| Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. | |
| | |
MedLine Citation:
|
PMID: 17521213 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
beta-Adrenoceptor antagonists (beta-blockers) have historically been considered an effective and safe option for first-line treatment of hypertension. However, very recently, it has been proposed that beta-blockers should no longer be considered suitable for first-line therapy in the patient with uncomplicated hypertension because of unfavourable morbidity and mortality data. New evidence from recent clinical studies of nebivolol, a third-generation highly selective beta(1)-blocker with additional endothelial nitric oxide (NO)-mediated vasodilating activity, confirms previous findings that this drug differs from other beta-blockers. The combined mechanisms of beta-adrenoceptor antagonism and NO-mediated vasodilation may potentiate the blood pressure-lowering effect of this agent, and confer a broader favourable metabolic profile, which may be clinically relevant for hypertensive patients. The antioxidant properties of nebivolol and its neutral or even favourable effects on both carbohydrate and lipid metabolism are well documented. These properties consistently differentiate nebivolol from nonvasodilating beta-blockers such as atenolol, metoprolol or bisoprolol. Therapeutic indications for beta-blockers include a wide range of co-morbidities found in hypertensive patients, including ischaemic heart disease, tachyarrhythmias and heart failure. Given that the majority of hypertensive patients require more than one drug to control blood pressure, the multiple mechanisms of action and favourable metabolic profile of nebivolol could make it an alternative therapeutic option for hypertensive patients requiring beta-adrenoceptor therapy. |
| | |
Authors:
|
Enrico Agabiti Rosei; Damiano Rizzoni |
Related Documents
:
|
7374093 - Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catech... 6113543 - Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure an... 3818183 - The synergistic effect of angiotensin ii and urea on systemic blood pressure. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 67 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2007 |
Date Detail:
|
Created Date: 2007-05-24 Completed Date: 2007-08-10 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 1097-107 Citation Subset: IM |
Affiliation:
|
Department of Medical and Surgical Sciences, Clinica Medica, University of Brescia, Brescia, Italy. agabiti@med.unibs.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
pharmacology*,
therapeutic use Antihypertensive Agents / pharmacology*, therapeutic use Antioxidants / pharmacology*, therapeutic use Benzopyrans / pharmacology*, therapeutic use Blood Glucose / drug effects Cholesterol / blood Clinical Trials as Topic Diabetes Mellitus / metabolism Dyslipidemias / complications, metabolism Endothelium, Vascular / drug effects, physiopathology Ethanolamines / pharmacology*, therapeutic use Heart Failure / complications Humans Hypertension / complications, drug therapy Lipids / blood Nitric Oxide / biosynthesis Oxidative Stress / drug effects Vasodilation / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Antioxidants; 0/Benzopyrans; 0/Blood Glucose; 0/Ethanolamines; 0/Lipids; 10102-43-9/Nitric Oxide; 57-88-5/Cholesterol; 99200-09-6/nebivolol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predictive study of charge transport in disordered semiconducting polymers.
Next Document: Hormone-refractory prostate cancer: where are we going?